3SBio Subsidiary Strikes Key Weight Management Drug Deal
Company Announcements

3SBio Subsidiary Strikes Key Weight Management Drug Deal

3SBio (HK:1530) has released an update.

3SBio Inc.’s subsidiary, Sunshine Mandi, has inked a lucrative cooperation agreement with Hybio Pharmaceutical for the joint development and exclusive supply of Semaglutide Injection, a weight management product. Under the deal, Sunshine Mandi is set to make milestone payments up to RMB 270 million to Hybio, including preclinical results, exclusive purchase prices, and profit-based royalties. The partnership aims to market and commercialize the product, with Sunshine Mandi holding exclusive marketing rights in certain regions and Hybio handling production.

For further insights into HK:1530 stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks HongKong Auto-Generated Newsdesk3SBio Secures Exclusive Rights for Cancer Drug
TipRanks HongKong Auto-Generated Newsdesk3SBio Issues Supplemental Share Grant Info
TipRanks HongKong Auto-Generated Newsdesk3SBio Awards Shares to Top Performers
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App